In: Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, vol. 388, no. 1, p. 43-49
|
In: European Journal of Clinical Pharmacology, 2015, vol. 71, no. 8, p. 1025-1026
|
In: Future Medicinal Chemistry, 2013, vol. 5, no. 2, p. 175-188
Since the discovery that CO acts as a cytoprotective and homeostatic molecule, increasing research efforts have been devoted to the exploitation of its therapeutic effects. Both endogenous and exogenous CO improves experimental lung, vascular and cardiac injuries and protects against several inflammatory states. The technology is now in place to bring CO to clinical applications, but the use...
|
In: Cancers, 2020, vol. 12, no. 3, p. 532
Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments. However, de novo and acquired PARP inhibitor resistance is a significant limiting factor in the clinical therapy, and the underlying mechanisms are not fully understood. Activity of the cytoprotective phosphatidylinositol-3 kinase...
|
In: Heart and Vessels, 2014, vol. 29, no. 6, p. 855-863
|
In: Journal of Anesthesia, 2014, vol. 28, no. 4, p. 580-586
|
In: Biochemical Pharmacology, 2019, vol. 162, p. 98–108
The cytoprotective effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition is well documented in various cell types subjected to oxidative stress. Previously, we have demonstrated that PARP1 inhibition activates Akt, and showed that this response plays a critical role in the maintenance of mitochondrial integrity and in cell survival. However, it has not yet been defined how nuclear PARP1...
|
In: Journal of Muscle Research & Cell Motility, 2003, vol. 24, no. 2-3, p. 219-249
|
In: Molecular and Cellular Biochemistry, 2010, vol. 340, no. 1-2, p. 239-247
|
In: Molecular and Cellular Biochemistry, 2008, vol. 313, no. 1-2, p. 133-138
|